Mohamed Isam Sharif

Mohamed Isam Sharif

Auto-generated profile, based on publicly available information

Mohamed Isam Sharif

Department of Hematology, Stem Cell Transplant and Cellular Therapy, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2025 in Leukemia Research Reports
Verified
Journal Article
Open access
MSMohamed I Sharif
Mohamed I Sharif
AAAhmad S. Alotaibi
Ahmad S. Alotaibi
RARuah Alyamany
Ruah Alyamany
AAAli Alahmari
Ali Alahmari
HAHanan Alkhaldi
Hanan Alkhaldi
MAMansour Alfayez
Mansour Alfayez
Acute myeloid leukemia (AML) is a heterogeneous disease with diverse molecular cytogenetic characteristics. Philadelphia-positive acute myeloid leukemia, a rare subtype of AML, is traditionally considered a high-risk, with the standard recommendation being an allogeneic hematopoietic cell transplant (HCT) in first remission. More recently, with better characterization and understanding of AML biology, novel therapies have been introduced. Drawing parallels from the advances seen in Philadelphia-positive acute lymphoblastic leukemia (ALL), the question arises whether potent tyrosine kinase inhibitors (TKI), such as ponatinib, in combination with AML-directed therapies, could be used in Philadelphia-positive AML, potentially eliminating the need for HCT in the first remission.

30 May 2026 in Blood Global Hematology
Verified
Journal Article
Open access
CLChokri Ben Lamine
Chokri Ben Lamine
NANourah Alzaidy
Nourah Alzaidy
MSMohamed Isam Sharif
Mohamed Isam Sharif
AHAmal Hejab
Amal Hejab
MSMarwan Shaheen
Marwan Shaheen
NCNaeem A. Chaudhri
Naeem A. Chaudhri